Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 1999

View Archived Issues

New antimalarial korupensamines available for licensing from NIH

Diatide receives patent protection for novel cancer pain treatment

Oxis announces initial results of phase IIa clinical trial in ulcerative colitis

Metabolex enters into diabetes partnership with Parke-Davis

Cubist files IND to begin phase III clinical trials of daptomycin

Chromanylsulfonyl(thio)ureas in early development at Hoechst Marion Roussel

Sigma ligands synthesized at Jouveinal, evaluated and claimed for GI disorders

Novel cocaine analogues with promise in the treatment of cocaine addiction or overdose

Modulators of multidrug resistance described in patent literature by Ontogen

Protease inhibitors especially useful for osteoporosis, periodontitis and arthritis reported by SB

Taisho isolates antifungal compound from Streptomyces

New hope for AMD sufferers: verteporfin proves effective and safe in TAP investigation

Phase III study of PhotoPoint therapy in AMD enrolling patients

Positive adult meningitis study results reported for pleconaril

Genelabs and DuPont renew collaboration on novel compounds that regulate gene expression

Mexiletine effectively controls spasmodic torticollis in treatment-refractory patients

Adoptive immunotherapy for HIV infection shows potential in phase I study

Overview of three promising new antifungal drugs in development

Histamine H3 antagonist ciproxifan shows positive behavioral effects in animal models

ProScript and NCI enter collaboration for development of anticancer therapeutic

Shire updates R&D pipeline

Pharmacokinetic profile of edaravone, a novel antioxidant from Mitsubishi Chemical

Creative BioMolecules licenses neurotrophic protein from Cambridge NeuroScience

FDA approves home use of Lovenox in patients with potentially life-threatening blood clots

Ethyol for reducing radiation-induced xerostomia in head and neck cancer filed with FDA

Mycophenolate mofetil potentiates antiherpesvirus activity of aciclovir

Rhoxalpharma now operating as independent generic pharmaceutical company

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...